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Abstract
Background: To consolidate literature reports of serious late gastrointestinal toxicities after hypofractionated
radiation treatment of pancreatic cancer and attempt to derive normal tissue complication probability (NTCP)
parameters using the Lyman-Kutcher-Burman model.
Methods: Published reports of late grade 3 or greater gastrointestinal toxicity after hypofractionated treatment of
pancreatic cancer were reviewed. The biologically equivalent dose in 1.8 Gy fractions was calculated using the EQD
model. NTCP parameters were calculated using the LKB model assuming 1–5 % of the normal tissue volume was
exposed to the prescription dose with α/β ratios of 3 or 4.
Results: A total of 16 human studies were examined encompassing a total of 1160 patients. Toxicities consisted of
ulcers, hemorrhages, obstructions, strictures, and perforations. Non-hemorrhagic and non-perforated ulcers occurred
at a rate of 9.1 % and were the most commonly reported toxicity. Derived NTCP parameter ranges were as follows:
n = 0.38–0.63, m = 0.48–0.49, and TD50 = 35–95 Gy. Regression analysis showed that among various study
characteristics, dose was the only significant predictor of toxicity.
Conclusions: Published gastrointestinal toxicity reports after hypofractionated radiotherapy for pancreatic cancer
were compiled. Median dose was predictive of late grade ≥ 3 gastrointestinal toxicity. Preliminary NTCP parameters
were derived for multiple volume constraints.
Background
With an overall 5-year survival of 5 % and a 5-year sur-
vival of 20 % after surgical resection, pancreatic cancer
has an extremely poor prognosis [1]. It is the 9th most
common malignancy in the United States, but the 5th
most common cause of cancer-related death [2]. The ag-
gressive nature of this cancer is partly due to its late presen-
tation and the intimate anatomic relationship between the
pancreas and adjacent structures, namely the duodenum,
stomach, liver, bile ducts, spleen, and the great vessels
and their branches. Whether surgical, pharmacological,
or radiological, any pancreatic treatment must attempt
to preserve the integrity and function of these structures.
The only potentially curative treatment for pancreatic
cancer is surgical, although chemotherapy or chemora-
diotherapy are often employed in the adjuvant setting
[3, 4]. Radiation therapy is also used in the setting of
unresectable disease for local control and symptomatic
palliation of pain and obstruction.
Conventionally fractionated treatments are lengthy,
may delay needed systemic therapy, and have not been
shown to be curative in unresectable disease. For these
reasons, hypofractionated schemes have sometimes been
employed, including stereotactic radiosurgery (SRS),
stereotactic body radiotherapy (SBRT), and intraopera-
tive radiotherapy (IORT).
Because of its close anatomic association with the pan-
creas and its relative radiosensitivity, the small bowel
and stomach are the major dose-limiting organs in radi-
ation treatment of the intact pancreas. Because of the
poor long-term survival of this patient population, acute
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side effects in the gastrointestinal tract are better char-
acterized than late effects. The objective of this work
was to compile literature reports of grade 3 or greater
late toxicities in hypofractionated radiation treatment
of pancreatic cancer and attempt to derive normal tissue
complication probability (NTCP) parameters using the
Lyman-Kutcher-Burman (LKB) model [5].
Methods
Review criteria
A series of PubMed searches were performed looking
for English-language original articles that reported
gastrointestinal toxicity in humans following treatment
of pancreatic cancer with external beam radiation ther-
apy. Over 200 papers fit our general search criteria, and
these were carefully screened for papers that reported
serious (grade 3 or above) late gastrointestinal complica-
tions from treatment with hypofractionated radiother-
apy, without regard to technique. An attempt was made
to select papers with specific mention of duodenal tox-
icity, but we also included papers reporting late effects
in the stomach, small intestine, and other gastrointes-
tinal organs. We also made an effort to avoid studies of
patients whose complications were reported in previous
publications. For the purposes of this review, late com-
plications were considered to be those that occurred
after a minimum of 3 months of follow-up. The eligible
articles were published from 1981 to 2013.
Equivalent dose calculation and nomenclature
The biologically equivalent dose in f Gy fractions for a
total dose D Gy given in d Gy fractions using an r α/β
ratio is defined as:
EQDfr ¼ D
d þ r
f þ r
 
For example, 60Gy3
2 means a biologically equivalent
dose of 60 Gy in 2 Gy fractions using an α/β ratio of 3.
To simplify the comparison of different hypofractionated
schedules, we will use biologically equivalent doses de-
fined in standard 1.8 Gy fractions, i.e.:
EQD1:8r ¼ eGy1:8r ¼ D
d þ r
1:8þ r
 
NTCP LKB Model, Maximum likelihood fitting, and
confidence intervals
Normal tissue complication probity (NTCP) were calcu-
lated using the Lyman-Kutcher-Burman (LKB) model as
follows [5]:
NTCP ¼ 1ﬃﬃﬃﬃﬃﬃ
2π
p
Zt
−∞ e−
x2
2
dx
where t is defined as
t ¼ Deff −TD50
mTD50
, and Deff is
Deff ¼
X
i
viDi
1=n

n
and represents the dose that if distributed evenly
across the volume, produces the same complication
probability as the actual dose distribution represented by
the summation. Variables vi and Di are the volume and
dose of each bin of the dose volume histogram (DVH).
Because the original DVH data was unavailable, hypo-
thetical DVHs were constructed assuming 1–5 % of the
duodenum received the study’s prescribed dose while the
remaining volume received no dose. TD50 is the dose
that produces a 50 % complication probability if deliv-
ered uniformly to the organ. The variable m relates to
the slope of the integral of the normal distribution and n
denotes if the tissue is parallel or serial. Optimal solu-
tions were obtained using the maximum likelihood
method by maximizing the following function:
lnL ¼
X
i
ni−qið Þ ln 1−NTCPið Þ þ qi ln NTCPið Þf g;
such that ni represents the total number of patients and
qi the number of patients that developed complications
within bin i of radiation dose. The profile likelihood
method was then used to calculate 95 % confidence inter-
vals for TD50, m, and n [6].
Statistical analysis
Linear regression model was used in univariate analysis
of toxicity rate. Variables of interest included median
follow-up, radiation dose level, number of dose fractions,
% of patients receiving chemotherapy, % of patients re-
ceiving surgery, and median overall survival. All statis-
tical tests were two-sided using an α = 0.05 level of
significance. SAS version 9.3 (Cary, NC) was used to
perform the above statistical analysis.
Results
Study characteristics
A total of 16 human studies and two canine studies were
examined and are summarized in Tables 1 and 2 [7–24].
Two studies included characteristic and outcome data
for two separate cohorts and were therefore analyzed in-
dependently [19, 21]. The total number of patients
treated was 1160 with a median of 60 patients per study
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(range: 19–210). The median length of follow-up in
months among studies that reported a follow-up time
was 11.6 (range 3–28). The median EQD4
1.8 was 125 Gy
(range: 50–209).
Toxicity
Serious gastrointestinal toxicities consisted of ulcers,
hemorrhages, obstructions, strictures, and perforations.
The median late grade 3 or greater GI toxicity among all
studies was 7.4 % (range: 0–32.7 %). The most frequently
reported toxicity, with a median rate of 9.1 % (range:
3.9–20 %), was ulcers that were neither hemorrhagic nor
perforated. The highest rates of ulceration occurred in
the two cohorts of Nishimura and colleagues (9.9 % and
20 %) [20]. Not surprisingly, the median dose used in
these two cohorts was higher than any other study that
reported non-hemorrhagic and non-perforated ulcers
(EQD4
1.8 178 and 209, respectively). The patients in the
cohort that experienced a 20 % ulcer rate had resectable
tumors and underwent either pancreatectomy or pan-
creaticoduodenectomy, while the cohort with a 9.9 %
ulceration rate had unresectable tumors [20]. Hemor-
rhages, which consisted of hemorrhagic ulcers or ero-
sions in the stomach, duodenum, or colon, occurred at
a median of rate of 4.6 % (range: 0.95–11.9 %). A median
of 3.6 % (range: 1.3–5.0 %) and 3.1 % (range: 0.60–5.2 %)
of patients developed perforations and strictures/obstruc-
tions, respectively.
There were four reported fatalities in the studies ana-
lyzed. Willett and colleagues reported two deaths from
treatment-related upper GI bleeding at 37 and 53 months
after treatment [18]. The patients in this study all re-
ceived IORT, EBRT, and 5-fluorouracil with a median
EQD4
1.8 of 133 Gy. Okamoto and colleagues reported a
fatality 11 months after treatment from a hemorrhagic
ulcer in a patient that had undergone a distal pancrea-
tectomy previously [21]. The exact dose used in this pa-
tient was not reported, but the median dose of the
cohort was 20 Gy IORT and 50 Gy EBRT postoperatively
(total EQD4
1.8 135 Gy). This study also reported a fatality
due to an esophageal variceal rupture 38 months after
treatment. This patient also underwent pancreaticoduo-
denectomy. The cause of death was deemed to be re-
lated to irradiation as the patient was found to have a
portal vein thrombosis and obstruction on CT scan.
Canine data
Toxicity rates from canine studies are summarized in
Table 2. Ahmadu-Suka and colleagues treated the abdo-
men of dogs with a single fraction IORT dose up to
40 Gy followed by 50 Gy of EBRT two weeks after sur-
gery [23]. Dogs treated with 17.5 or 25 Gy IORT disease
(EQD4
1.8 126 and 177, respectively) showed mucosal at-
rophy, but did not show any duodenal ulcers on autopsy
4.5 months after treatment. Dogs surviving greater than
3 months and treated with 32.5 Gy IORT (EQD4
1.8 256)
all showed ulcers on autopsy, and 25 % were perforated.
Among the dogs surviving longer than 3 months and
treated with 40 Gy IORT (EQD4
1.8 355), all experienced
duodenal ulcers, and 75 % were perforated.
Halberg and colleagues examined the duodenum of
dogs 6 months after treatment with 30 Gy IORT
(EQD4
1.8 176) in the presence of intraluminal WR-2721
or vehicle control [24]. The two dogs in the control co-
hort that survived to 6 months both showed grade 3
duodenal ulcers on autopsy.
NTCP model
Lyman NTCP model parameters and corresponding
95 % confidence intervals for human GI toxicity data are
summarized in Table 3. Because dose volume histograms
were not available, we estimated parameters assuming 1
to 5 % of the duodenum received the study’s prescribed
dose. If multiple doses or fractionation schemes were
employed in a single study, the median study dose was
used for our analysis. In some instances, the median
study dose was not provided and could not be calculated
because the exact dose distribution was not reported. In
these limited cases, the mean dose as reported by the
authors was used. According to published reports, an
α/β ratio of 3.0 or 4.0 is appropriate for bowel toxicity,
thus we estimated the median or mean EQD4
1.8 using a
α/β ratio of 3 or 4 (Table 3) [25, 26]. Figure 1 shows
overall GI toxicity rate as a function of median or mean
dose for each study and the maximum likelihood fit of
the LKB model for α/β ratio of 3 and 4 and duodenal
volume 1 % and 100 % (Fig. 1).
Univariate logistic regression
We performed univariate analysis to determine the effect
of follow-up time, dose, overall survival, primary modal-
ity of radiotherapy (SBRT vs. IORT), number of frac-
tions, percentage of patients receiving chemotherapy,
and percentage of patients undergoing surgery on the
overall gastrointestinal toxicity rate. Dose was the only
significant predictor of GI toxicity (Table 4).
Discussion
Tissue complications from radiation therapy can present
in early and late phases. Early complications in the
bowel are related to acute mucosal injury. Denudation of
the rapidly dividing epithelial cells that line the gastro-
intestinal tract can result in nausea, vomiting, gastritis,
and/or diarrhea. These early effects are usually transient,
beginning less than a week after the first dose and re-
solving soon after the last treatment. Late complications,
on the other hand, may appear within a few months of
treatment and result from fibrotic changes to the bowel
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Table 1 Human GI toxicity rates from studies using hypofractionated radiotherapy for pancreatic cancer
Author
(reference)
N Median
follow-up
(months)
Radiotherapy EQD4
1.8 Chemo
(%)
Surgery
(%)
Late GI complications Complication
rate
Total GI
toxicity
rate
Mahadevan
et al. [7]
36 24 30 Gy 3 fxa
(median)
72 86.1 % None GI bleeding requiring transfusion, grade≥ 3 2/36 (5.6 %) 5.6 %
Mahadevan
et al. [8]
39 21 24 Gy 3 fxa
(median)
50 100 % None GI bleeding requiring transfusion, grade 3 2/39 (5.1 %) 7.7 %
Gastric outlet obstruction, grade 3 1/39 (2.6 %)
Lominska et
al. [9]
28 5.9 21 Gy 3 fxa +
50.4 Gyc
(median)
90 71 % 29 % Bowel obstruction, grade 3 1/28 (3.6 %) 7.1 %
Gastric perforation, grade 3 1/28 (3.6 %)
Chang
et al. [10]
77 6 25 Gy 1 fxa
(exact)
125 96 % None Biliary stricture, grade 3 2/77 (2.6 %) 9.1 %
Duodenal stricture, grade 3 1/77 (1.3 %)
Small bowel perforation, grade 4 1/77 (1.3 %)
Gastric ulcer, grade 3 3/77 (3.9 %)
Hoyer
et al. [11]
22 3 45 Gy 3 fxa
(median)
147 None 13.6 % Duodenum or stomach severe mucositisd 2/22 (9.1 %) 22.7 %
Duodenum or stomach ulcerationd 2/22 (9.1 %)
Stomach perforationd 1/22 (4.5 %)
Chuong
et al. [12]
73 10.5 30 Gy 5 fxa
(median)
52 100 % 56 % GI bleeding requiring embolization, grade 3 3/73 (4.1 %) 5.5 %
Anorexia resulting in feeding tube
placement, grade 3
1/73 (1.4 %)
Schellenberg
et al. [13]
20 11.8 25 Gy 1 fxa
(exact)
125 100 % None Duodenal perforation, grade≥ 3 1/20 (5.0 %) 5.0 %
Didolkar et
al. [14]
85 Unknown 25.5 Gy 3 fxa
(median)
55 100.0 % 16.5 % Late duodenitis (upper GI hemorrhage or
obstruction), grade≥ 3
7/85 (8.2 %) 8.2 %
Polistina et
al. [15]
23 9 30 Gy 3 fxa
(exact)
72 100 % None Late GI toxicity, grade≥ 3 0/23 (0 %) 0.0 %
Rwigema et
al. [16]
71 12.7 24 Gy 1 fxa
(median)
116 90 % 39 % Late GI toxicity, grade≥ 3 0/71 (0 %) 0.0 %
Ogawa
et al. [17]
210 26.3 25 Gy 1 fxb
(median)
125 54.3 % 100 % GI toxicity unspecified, grade 3 3/210 (1.4 %) 3.3 %
Colitis, grade 4 1/210 (0.5 %)
GI bleeding, grade 4 2/210 (1.0 %)
Ileus, grade 4 1/210 (0.5 %)
Willett
et al. [18]
150 17 20 Gy 1 fxb +
50.4 Gyc
(median)
133 100 % 82 % Bleeding secondary to duodenal ulcer or
erosion requiring medical interventiond
16/150 (10.6 %) 15.0 %
Fatal duodenal bleeding, Grade 5 2/150 (1.3 %)
Duodenal obstructiond 1/150 (0.6 %)
Abdominal wall dehiscenced 1/150 (0.6 %)
Otherd 2/150 (1.3 %)
Mohiuddin et
al. [19]
49 28 20 Gy 1 fxb +
50 Gyc (median)
133 100 % None Cholangitis, grade≥ 3 2/49 (4.1 %) 16.3 %
GI bleeding, gastric antrum or
transverse colon, grade≥ 3
3/49 (6.1 %)
Bowel obstruction, grade≥ 3 2/49 (4.1 %)
Enteritis, grade≥ 3 1/49 (2 %)
Nishimura et
al. [20]
55 Unknown 26 Gy 1 fxb +
44 Gyc (mean)
178 34.2 % 100 % GI ulcer (non-perforating)d 11/55 (20.0 %) 32.7 %
Intestinal perforationd 2/55 (3.6 %)
Abdominal abscessd 3/55 (5.5 %)
Ileusd 2/55 (3.6 %)
71 29.3 Gy 1 fxb +
41 Gyc (mean)
209 27.4 % None GI ulcer (non-perforating)d 7/71 (9.9 %) 19.7 %
Intestinal perforationd 2/71 (2.8 %)
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and its vasculature. Ischemia and fibrosis lead to mucosal
atrophy, ulceration, tissue breakdown, perforation, inflam-
mation, and the formation of strictures, obstructions, and
adhesions. Perforation of the duodenum is particularly
dangerous due to its close proximity to the vessels of the
mesentery and their branches. Better characterization of
late gastrointestinal toxicity is important for safe treatment
of patients with pancreatic cancer.
In an attempt to characterize late GI toxicity in hypo-
fractionated treatment of pancreatic cancer, we compiled
published gastrointestinal late toxicity data from mul-
tiple institutions. We reasoned that this approach, which
in total encompasses over a thousand patients across
multiple studies and institutions, would reveal gastro-
intestinal toxicity trends and patterns that may not be
apparent in studies with smaller cohorts. For example,
while ulcers were the most common observed toxicities
at a rate of 9.9 %, hemorrhages, perforations, and ob-
structions occurred at a rate of 3–5 % and might not be
appreciated in smaller studies.
We also examined the relationship between radiation
dose and late gastrointestinal complications. We specific-
ally examined studies that used hypofractionated treat-
ment irrespective of modality (between 1 and 5 fractions).
Several patients also received conventionally fractionated
radiotherapy. We calculated the EQD4
1.8 for all radiation
treatments given to the volume, and summed them arith-
metically. Whether the linear-quadratic model accurately
represents the true biologic efficacy of hypofractionated
radiation treatments is an issue of debate, especially when
the fraction size is large [27]. In our analysis, we noticed a
clear relationship between dose and toxicity (Fig. 1). Uni-
variate analysis of multiple study characteristics identified
dose as a significant predictor of toxicity (Table 4). A simi-
lar literature analysis attempting to identify a therapeutic
window for SBRT use in pancreatic adenocarcinoma by
Brunner and colleagues also identified a significant rela-
tionship between dose and gastrointestinal toxicity [28].
The authors compiled gastrointestinal toxicity from 16 lit-
erature reports following SBRT of the pancreas. Linear
Table 1 Human GI toxicity rates from studies using hypofractionated radiotherapy for pancreatic cancer (Continued)
Abdominal abscessd 1/71 (1.4 %)
Duodenal fibrosisd 3/71 (4.2 %)
Ileusd 1/71 (1.4 %)
Okamoto et
al. [21]
68 Unknown 20 Gy 1 fxb + 50
Gyc (median)
135 8.8 % 94.1 % Duodenal ulcer, bleedingd 2/68 (2.9 %) 2.9 %
64 20 Gy 1 fxb + 50
Gyc (median)
135 None 100 % Duodenal ulcer, fatal hemorrhagic shock,
grade 5
1/64 (1.6 %) 1.6 %
Goldson et
al. [22]
19 Unknown 22.5 Gy 1 fxb
(median)
102 None None GI ulcers, bile duct obstructiond 2/19 (10.5 %) 10.5 %
aSBRT
bIORT
cEBRT
dGrade not specified, but presumed to be a grade ≥ 3 toxicity
Table 2 Canine GI toxicity rates from studies using hypofractionated radiotherapy
Author (reference) Nc Median follow-Up
(months)
Radiotherapy EQD4
1.8 Chemo
(%)
Surgery
(%)
Late GI complications Complication
rate
Total GI
toxicity rate
Ahmadu-Suka et
al. [23]
4 4.8 17.5 Gy 1 fxa + 50 Gyb
(exact)
126 none 100 % 0/4 (0 %) 0 %
3 25 Gy 1 fxa + 50 Gyb
(exact)
177 none 100 % 0/3 (0 % 0 %
4 32.5 Gy 1 fxa + 50 Gyb
(exact)
256 none 100 % Non-perforated duodenal
ulcersd
3/4 (75 %) 100 %
Perforated ulcersd 1/4 (25 %)
4 40 Gy 1 fxa + 50 Gyb
(exact)
355 none 100 % Non-perforated duodenal
ulcersd
1/4 (25 %) 100 %
Perforated ulcersd 3/4 (75 %)
Halberg
et al. [24]
2 6 30 Gy 1 fxa (exact) 176 none 100 % Duodenal ulceration,
grade 3
2/2 (100 %) 100 %
aIORT
bEBRT
cNumber of dogs surviving ≥ 3 months
dGrade not specified
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regression showed a positive correlation between grade ≥ 3
toxicity and study EQD3
2 (R2 = .77). A 5 % rate of grade ≥ 3
toxicity was associated with an EQD3
2 of 80 Gy. Interest-
ingly, examining the raw data for Fig. 1 based on a similar
EQD3
1.8, the 5 % complication rate is reached at 80 Gy, and
with an EQD4
1.8 the 5 % complication rate is reached at
75 Gy. Therefore, both studies seem consistent in this
respect.
Because dose volume histograms were not available,
we estimated NTCP model parameters assuming duo-
denal volumes of 1–5 % received the prescription dose,
which is consistent with clinical practice and as reported
in some of the series we examined. For example, Chang
and colleagues as well as Schellenberg and colleagues
treated patients with 25 Gy in a single fraction using
SBRT. In both studies, the volume of duodenum receiv-
ing more than 22.5 Gy was less than 5 % [10, 13]. Willett
and colleagues as well as Goldson and colleagues
retracted normal GI structures away from the cylinder
applicator when treating patients with IORT [18]. Nishi-
mura and colleagues similarly retracted normal GI struc-
tures outside the treatment field. In cases where the GI
structures could not be completely excluded, a smaller
dose was applied to the entire field and a higher dose
applied to the central region targeting the tumor (field-
in-field). Thus, an upper limit of 5 % of duodenal vol-
ume exposed to the maximum dose seems reasonable.
Derived NTCP LKB model parameters for the com-
piled toxicity data set are shown in Table 3. TD50 values
ranged from 35 to 95 Gy and represent clinically plaus-
ible constraints. Early work by Burman et al. analyzing
toxicity data compiled by Emami and colleagues ob-
tained TD50 values of 55 for small intestine and 65 Gy
for stomach [29, 30]. Prior and colleagues attempted a
similar analysis on compiled duodenal and small bowel
toxicity using a modified linear quadratic model of mul-
tiple fractionation schedules and derived a TD50 value of
60.9 Gy [31]. Murphy and colleagues derived NTCP pa-
rameters for patients receiving a single 25 Gy dose using
SBRT for pancreatic cancer and obtained a TD50 value of
24.6 Gy (single fraction) [32]. Not surprisingly, our TD50
values were highly dependent on duodenal volume as-
sumptions (Table 3). Indeed, Murphy and colleagues
performed a dose volume analysis of GI toxicity in pa-
tients treated with 25 Gy in a single fraction and found a
significant association between duodenal volume and
toxicity [32]. Availability of DVHs corresponding to
Table 3 NTCP LKB parameters of pooled human GI toxicity
studies. An α/β ratio of 3 or 4, median or mean study EQD, and
duodenal volumes of 1–5 % were used for analysis. Parameters
and corresponding 95 % confidence intervals as calculated by
the profile likelihood method are shown
NTCP model
assumptions
NTCP model parameters
α/β Volume n (95 % CI) m (95 % CI) TD50 (95 % CI)
3 1 % 0.50 (0.47–0.53) 0.49 (0.46–0.52) 41.0 (36.2–47.4)
3 2 % 0.38 (0.35–0.42) 0.49 (0.46–0.52) 91.0 (80.3–105.4)
3 3 % 0.42 (0.38–0.46) 0.49 (0.46–0.52) 95.0 (83.9–110.1)
3 4 % 0.50 (0.46–0.54) 0.49 (0.46–0.52) 81.9 (72.3–94.9)
3 5 % 0.63 (0.58–0.67) 0.49 (0.46–0.52) 63.0 (55.6–72.9)
4 1 % 0.48 (0.45–0.51) 0.48 (0.45–0.51) 39.0 (34.7–44.7)
4 2 % 0.59 (0.56–0.62) 0.48 (0.45–0.51) 35.0 (31.1–40.1)
4 3 % 0.45 (0.42–0.50) 0.48 (0.45–0.51) 71.0 (63.1–81.5)
4 4 % 0.45 (0.42–0.50) 0.48 (0.45–0.51) 81.0 (71.9–92.9)
4 5 % 0.43 (0.40–.48) 0.48 (0.45–0.51) 95.0 (84.4–109.1)
Fig. 1 Human late GI toxicity as a function of fraction corrected median or mean study dose (EQD1.8) for α/β of 3 (a) and 4 (b) and corresponding LKB
model assuming duodenal volume receiving the prescription dose of 1 % and 100 %. DV = duodenal volume
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toxicity would allow the prediction of more accurate and
clinically applicable NTCP parameters and highlights the
need for multi-institutional treatment toxicity databases.
While differences in treatment (i.e., use of chemotherapy
or surgery) or patient characteristics across institutions
may affect toxicity rates, our analysis suggests that dose
is the primary predictor of toxicity (Table 4). Other im-
portant and potentially confounding variables such as
median follow-up, median survival, use of chemother-
apy, or surgery, were not significant.
There are many limitations to our approach. We ex-
amined the relationship of total dose to late GI toxicity
rate and did not study the relationship of dose to the
specific type of complication reported (e.g., ulceration,
bleeding, perforation). Many of the studies we analyzed
reported a range of doses given to their patient cohort,
and the majority did not report the specific dose corre-
sponding to each reported toxicity. Thus, identifying
threshold doses for serious GI complications was diffi-
cult. To circumvent this limitation in reporting, median
study dose was used. This approach clearly has the po-
tential to confound the relationship between radiation
dose and toxicity rate. Our analysis is also limited by the
lack of consideration of the variability in the partial vol-
ume of duodenum irradiated among different studies.
While we attempted to model the effect of partial vol-
ume by assuming uniform volumes of 1–5 % across all
studies, assuming a single volume for all studies will
likely introduce error. Differences among reporting strat-
egies, modality, contouring of normal structures, and
general patient variability could all be sources of vari-
ability within the data. We attempted to identify sources
of variability within the data by performing univariate
regression analysis, which identified fraction-adjusted
dose as the only significant predictor of toxicity.
Conclusions
In conclusion, we have aggregated and analyzed late
gastrointestinal toxicity data from studies utilizing hypo-
fractionated treatment for pancreatic cancer. Reported
toxicities consisted of ulcers, hemorrhages, obstructions,
strictures, and perforations. Non-hemorrhagic ulcers
were the most frequent complication and occurred in
approximately 9.1 % of patients. We also observed a re-
lationship between study dose and rates of late grade ≥ 3
gastrointestinal toxicity and have derived preliminary
NTCP LKB model parameters. Additional studies using
individual patient data, with access to dose volume dis-
tributions and individual histories and toxicity reports,
would allow us to better characterize the dose–response
relationship for gastrointestinal toxicity in hypofractio-
nated radiation treatment. A multi-institutional pro-
spectively maintained treatment database would allow a
more accurate analysis to be performed in the future.
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